Niagen Bioscience, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 56/100
What the filing says
Niagen reported Q2 2026 net sales of $29.8M (down 4% YoY from $31.1M), with Tru Niagen generating $24.2M. The company launched its proprietary drug candidate NB4168 targeting rare genetic disease Ataxia-Telangiectasia (A-T), which received FDA Rare Pediatric Disease designation and European Orphan Medicinal Product designation. NB4168 preclinical studies with Evotec begin Q3 2026. Niagen Plus telehealth platform launched with LegitScript certification; company added Olympia Pharmaceuticals as 503B compounder. Net income was $1.0M with $3.0M adjusted EBITDA; cash position $66.7M with no debt. DTC e-commerce grew 23% YoY to $20.5M.
Why this rating
Pharma program launch is strategically important long-term but early-stage preclinical; modest near-term impact. Sales decline, positive cash flow offset. Meaningful for strategy, not yet material to $814M market cap.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.